Mineralys Therapeutics, Inc. (MLYS)
| Market Cap | 1.91B-42.5% |
| Revenue (ttm) | n/a |
| Net Income | -349.58M |
| EPS | -4.22 |
| Shares Out | 88.41M |
| PE Ratio | n/a |
| Forward PE | -8.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 151,657 |
| Open | 22.00 |
| Previous Close | 22.09 |
| Day's Range | 21.46 - 22.07 |
| 52-Week Range | 21.46 - 47.65 |
| Beta | 0.69 |
| Analysts | none |
| Price Target | 48.50(+124.95%) |
| Earnings Date | Nov 10, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About MLYS
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MLYS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MLYS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MLYS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MLYS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MLYS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MLYS from public contracts
Source: USAspending.gov
MLYS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MLYS’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score